ArticlePloS one2026
Integrated transcriptome and single-cell sequencing analysis identify blood-pancreas shared lncRNA biomarkers in new-onset T2DM.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by β-cell dysfunction and insulin resistance, yet the early molecular drivers remain elusive. This study set out with the aim of identifying blood-pancreas shared long non-coding RNAs (lncRNAs) as potential systemic biomarkers in treatment-naïve patients with new-onset T2DM. We integrated transcriptome sequencing of peripheral blood from 8 T2DM patients and 8 controls with single-cell RNA sequencing (scRNA-seq) of pancreatic islets from an independent cohort. Differential expression analysis revealed 1,709 dysregulated lncRNAs in peripheral blood, of which 257 were identified as high-priority candidate through weighted gene co-expression network analysis (WGCNA). Further intersection with scRNA-seq data from 17 T2DM donors identified 157 β-cell-specific mRNAs co-expressed with 135 blood-derived lncRNAs. Functional enrichment analysis implicated these genes in chromatin remodeling, focal adhesion, and neurodegenerative pathways. Validation in an expanded cohort (85 T2DM vs. 85 controls) confirmed significant downregulation of ENST00000473095, MSTRG.90147.1 and ENST00000531992 in T2DM. The combined ROC-AUC value of these three lncRNAs was 0.73, which exceeds the AUCs of each individual lncRNA (0.61-0.64). Our findings tentatively suggest that blood-derived lncRNAs as early biomarkers reflecting β-cell stress and systemic dysregulation. These lncRNAs may potentially bridge peripheral blood biomarkers with tissue-specific pathophysiology in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.